HomeAI · summaries
Storia in 10 fonti
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
AstraZeneca stock dives 9% after heart drug trial misses target
A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.
- ·
endpoints.news
AstraZeneca sinks on unexpected heart drug trial failure
AstraZeneca shares sink up to 9% after Wainua misses cardiovascular endpoint in Phase 3 ATTR-CM trial with partner Ionis.
